Navigating adalimumab biosimilars: an expert opinion
This article explores the characteristics of various adalimumab biosimilars to help clinicians navigate the various options available across Europe and the USA. In addition to drug selection, effective patient-physician communication is needed to nurture realistic patient expectations and minimise potential nocebo effects when prescribing biosimilars.PMID:37855223 | DOI:10.57264/cer-2023-0117
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Authors: Vered Abitbol Salim Benkhalifa Caroline Habauzit Hubert Marotte Source Type: research
More News: General Medicine | Humira